Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Prothena ( (PRTA) ).
Prothena Corporation has announced a strategic leadership change as Dr. Hideki Garren steps down as Chief Medical Officer to join a major pharmaceutical company. Succeeding him is Dr. Chad Swanson, newly appointed Chief Development Officer, who brings over two decades of neuropharmacology experience to the role. This move is set against the backdrop of Prothena’s advancement in developing treatments for neurodegenerative and rare diseases, highlighting the company’s commitment to innovation in protein dysregulation and its robust R&D pipeline.
For a thorough assessment of PRTA stock, go to TipRanks’ Stock Analysis page.